N/A N=39 Glucocorticoids and Bone in Graves' Ophthalmopathy
Graves Ophthalmopathy
Primary: Percent Change Lumbar Spine Bone Mineral Density — 1.37 Percentage change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=25 Trial of Rituximab for Graves' Ophthalmopathy
Thyroid-associated Ophthalmopathy
Primary: Change in Clinical Activity Score (CAS) — -1.2; -1.5 units on a scale — p=0.73
Phase 2 N=7 Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
Graves' Ophthalmopathy
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment…
Phase 3 N=83 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study
Thyroid Eye Disease · Graves' Orbitopathy
Primary: Percentage of Participants Who Were Proptosis Responders at Week 24 — 9.5; 82.9 percentage of participants — p=<0.001
Phase 4 N=37 Rituximab (RTX) Therapy in Patients With Active TAO
Ophthalmopathy, Thyroid-Associated
Primary: Clinical Activity Score (a Composite Measure of Ophthalmological Signs and Symptoms) — 4.25; 2.77; 4.25; 4.20 score on a scale
Phase 3 N=51 Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
Thyroid Eye Disease
Primary: Percentage of Participants With a ≥ 2 mm Reduction From Baseline in the Study Eye Without Deterioration of Proptosis in the Fellow Eye at Week 24 — 89.2; 53.8 percentage…
N/A N=10 Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease
Thyroid Eye Disease
Primary: Change in IOP Before and After Orbital Decompression Surgery — 18 mVEq (Sensismed Triggerfish output unit)
Phase 1 N=12 ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
Graves Disease
Primary: Occurrence of Treatment Emergent Adverse Events (TEAE), Serious Adverse Events (SAE), and Laboratory Abnormalities up to Week 22 Compared to Baseline. — 311; 293; 18; 0…
Phase 2 N=87 Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
Thyroid Associated Ophthalmopathies · Thyroid-Associated Ophthalmopathy
Primary: Responder Status at Week 24 — 9; 29; 36; 13 Participants — p=< 0.001
N/A N=8 IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
GVHD · Ocular Rosacea · Dry Eye Syndrome
Primary: Number of Participants Who Responded to Intense Pulsed Light (IPL) — 5; 2 participants
N/A N=9 Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
Ocular Sarcoidosis · Panuveitis · Anterior Uveitis
Primary: Percentage of Patients With Clinically Significant Improvement in Visual Acuity — 3 Participants
Phase 3 N=61 Early Levothyroxine Post Radioactive Iodine
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
Phase 4 N=62 A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
Thyroid Eye Disease · Chronic (Inactive) Thyroid Eye Disease
Primary: Change From Baseline in Proptosis of Study Eye at Week 24 — -2.41; -0.92 Millimieter (mm) — p=0.0004
Phase 2 N=19 Radioactive Iodide Therapy for Pediatric Graves' Disease
Graves' Disease
Primary: Dosimetry Studies
Phase 4 N=36 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Graves Disease · Hyperthyroidism
Primary: Blood Loss During Surgery — 61.67; 161.67 mL
N/A N=12 Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
Non-Hodgkin's Lymphoma · Lymphoma
Primary: Number of Participants With Complete Response (CR) or Partial Response (PR) — 10; 2 participants
Phase 2 N=41 A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
Thyroid Eye Disease · Graves Ophthalmopathy · Graves Orbitopathy
Primary: Percentage of Participants Showing a Response in Proptosis Measured Using Hertel Exophthalmometer (≥2 mm Decrease From Baseline) in the Study Eye and Separately in…
Phase 2 N=25 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients
Graves Disease
Primary: CD80 Level — 45.60; 54.51 nM — p=0.48
Phase 2 N=3 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Ocular Cicatricial Pemphigoid
Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Phase 2 N=33 Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
Chronic Ocular Graft-versus-host Disease
Primary: Modified SANDE Questionnaire - Frequency, Change From Baseline — -22.00; -4.59 score on a scale — p=0.0197
N/A N=75 Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
Dry Eyes
Primary: Progression of Dry Eye Severity — 15; 12 patients with increased dry eye severity
Early Phase 1 N=15 Topical Bimatoprost for Chemical Blepharoplasty
Dermatochalasis
Primary: Graded Change in Dermatochalasis — .2679 units on a scale
Phase 2 N=35 Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
Chronic Graft-versus-host Disease
Primary: Change From Baseline (Visit 1) of Total Corneal Fluorescein Staining Score at 12 Weeks. — -4.2; -6.2; -2.1 units on a scale
Phase 2 N=11 OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
Geographic Atrophy · Age-Related Macular Degeneration · AMD
Primary: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. — 0.2; -11.3 ETDRS Letters
Phase 2 N=22 Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
Scleritis · Orbital Disease
Primary: Reduction of Medications — 5; 4 participants
Phase 1 N=40 Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease
Ocular GVHD
Primary: Ocular Burning Sensation, Ocular Discharge, Ocular Redness, Ocular Itching, Foreign Body Sensation — 3.50; 2.23; 0.16; 0.26 units on a scale — p=0.0019
Phase 2 N=20 Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease
Graft Versus Host Disease · Ophthalmologic Complications
Primary: Change in Patient-reported Symptoms Measured by the 8-point Lee Eye Subscale — 75.4; 63.2; 61.8; 56.3 units on a scale — p=0.01
Phase 4 N=30 Preoperative Steroids in Autoimmune Thyroid Disease
Thyroid Diseases
Primary: Thyroid Difficulty Scale Score — 9.8; 9.75 score on a scale
Phase 2 N=90 Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Primary: Lower Eyelid Steatoblepharon Severity (LESS) Score--Clinician-Reported — 27; 6 participants — p=0.020